Coupland S E, Heimann H
Institut für Pathologie, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin.
Ophthalmologe. 2004 Jan;101(1):87-98. doi: 10.1007/s00347-003-0855-6.
Primary intraocular lymphoma (PIOL) is a rare extranodal Non-Hodgkin lymphoma (NHL), involving the retina, the subretinal space, vitreous body and/or optic nerve. The majority of PIOL are diffuse large cell B-cell lymphomas according to the new W.H.O. lymphoma classification with an immunophenotype suggesting an origin from germinal centre cells. PIOL occurs independently or together with primary central nervous system lymphoma (PCNSL), and often presents in the form of a steroid-resistant uveitis. PIOL is one of the most challenging intraocular tumours to diagnose. Cytological examination of vitreal aspirates remains the gold standard for exclusion of neoplastic disease in patients with idiopathic uveitis. Various techniques, particularly the polymerase chain reaction analysing clonal rearrangements of the immunoglobin heavy chain or the T-cell receptor genes, prove to be useful adjuncts. Chorioretinal biopsies increase the chances of diagnosing or excluding a PIOL involving the retina and choroid. Furthermore, they allow exact subtyping of the malignant lymphoma when present, enabling exclusion of an ocular manifestation of a systemic lymphoma. Currently, most PIOL/PCNSL are treated with systemic chemotherapy. Ocular recurrences are often treated with radiotherapy, and increasingly with intraocular methotrexate. Although the prognosis of patients with PCNS/PIOL remains poor, newer methods enabling earlier diagnosis establishment and treatment are gradually increasing overall survival.
原发性眼内淋巴瘤(PIOL)是一种罕见的结外非霍奇金淋巴瘤(NHL),累及视网膜、视网膜下间隙、玻璃体和/或视神经。根据世界卫生组织新的淋巴瘤分类,大多数PIOL为弥漫性大细胞B细胞淋巴瘤,其免疫表型提示起源于生发中心细胞。PIOL可独立发生或与原发性中枢神经系统淋巴瘤(PCNSL)同时发生,常表现为对类固醇耐药的葡萄膜炎。PIOL是最难诊断的眼内肿瘤之一。玻璃体抽吸物的细胞学检查仍然是排除特发性葡萄膜炎患者肿瘤性疾病的金标准。各种技术,特别是分析免疫球蛋白重链或T细胞受体基因克隆重排的聚合酶链反应,被证明是有用的辅助手段。脉络膜视网膜活检增加了诊断或排除累及视网膜和脉络膜的PIOL的机会。此外,当存在恶性淋巴瘤时,它们可以对其进行准确的亚型分类,从而排除系统性淋巴瘤的眼部表现。目前,大多数PIOL/PCNSL采用全身化疗。眼部复发通常采用放射治疗,越来越多地采用眼内甲氨蝶呤治疗。尽管PCNS/PIOL患者的预后仍然很差,但能够更早确诊和治疗的新方法正在逐渐提高总体生存率。